[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN107531725A - Irak4抑制剂及其应用 - Google Patents

Irak4抑制剂及其应用 Download PDF

Info

Publication number
CN107531725A
CN107531725A CN201580078883.0A CN201580078883A CN107531725A CN 107531725 A CN107531725 A CN 107531725A CN 201580078883 A CN201580078883 A CN 201580078883A CN 107531725 A CN107531725 A CN 107531725A
Authority
CN
China
Prior art keywords
alkyl
compound
disease
inhibitor
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580078883.0A
Other languages
English (en)
Other versions
CN107531725B (zh
Inventor
薛宝玉
郑汝娜
车美英
金孟燮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Hanmi Pharmaceutical Co Ltd
Original Assignee
Beijing Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Hanmi Pharmaceutical Co Ltd filed Critical Beijing Hanmi Pharmaceutical Co Ltd
Publication of CN107531725A publication Critical patent/CN107531725A/zh
Application granted granted Critical
Publication of CN107531725B publication Critical patent/CN107531725B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及抑制IRAK4激酶活性的化合物、其药物组合物、其在制药中的用途、使用其抑制IRAK4激酶活性的方法以及使用其治疗和/或预防哺乳动物(尤其是人)中IRAK4激酶介导的疾病或病症的方法。所述化合物具有结构式I。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201580078883.0A 2015-08-13 2015-08-13 Irak4抑制剂及其应用 Active CN107531725B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/086894 WO2017024589A1 (zh) 2015-08-13 2015-08-13 Irak4抑制剂及其应用

Publications (2)

Publication Number Publication Date
CN107531725A true CN107531725A (zh) 2018-01-02
CN107531725B CN107531725B (zh) 2021-03-19

Family

ID=57982884

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580078883.0A Active CN107531725B (zh) 2015-08-13 2015-08-13 Irak4抑制剂及其应用

Country Status (6)

Country Link
US (1) US10988482B2 (zh)
EP (1) EP3336091B1 (zh)
JP (1) JP6851367B2 (zh)
KR (1) KR102110573B1 (zh)
CN (1) CN107531725B (zh)
WO (1) WO2017024589A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017205766A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2019001460A1 (zh) * 2017-06-27 2019-01-03 南京明德新药研发股份有限公司 作为 irak4 抑制剂的稠环化合物
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
WO2020068854A1 (en) * 2018-09-25 2020-04-02 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound
US20230146395A1 (en) * 2020-03-09 2023-05-11 Verge Analytics, Inc. Substituted Pyrimidines and Uses Thereof
CN115916747A (zh) * 2020-07-01 2023-04-04 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
JP2023548190A (ja) * 2020-11-05 2023-11-15 ハンミ ファーマシューティカル カンパニー リミテッド 骨髄性白血病の治療のためのｆｌｔ３阻害剤を含む医薬組成物
WO2023201272A1 (en) 2022-04-12 2023-10-19 Genzyme Corporation Use of irak4 modulators for gene therapy
WO2024114704A1 (zh) * 2022-11-30 2024-06-06 深圳众格生物科技有限公司 新型irak4抑制剂以及抑制并降解irak4蛋白的化合物及其制备方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105056A2 (en) * 2005-03-28 2006-10-05 Fmc Corporation Insecticidal 2,4-diaminoquinazolines and related derivatives
JP2008013527A (ja) * 2006-07-10 2008-01-24 Sankyo Co Ltd チエノ［３，２−ｄ］ピリミジン−２，４−ジアミン誘導体
CN102066338A (zh) * 2008-04-22 2011-05-18 波托拉医药品公司 蛋白激酶抑制剂
CN103442568A (zh) * 2010-10-08 2013-12-11 Abbvie公司 呋喃并[3,2-d]嘧啶化合物
WO2014011911A2 (en) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2015039612A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
WO2015048281A1 (en) * 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507536A (ja) 2014-12-18 2018-03-15 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 磁気熱量カスケード及び磁気熱量カスケードの製造方法
CN106188060A (zh) 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
CN107531710B (zh) 2015-08-13 2020-02-14 北京韩美药品有限公司 Irak4抑制剂及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105056A2 (en) * 2005-03-28 2006-10-05 Fmc Corporation Insecticidal 2,4-diaminoquinazolines and related derivatives
JP2008013527A (ja) * 2006-07-10 2008-01-24 Sankyo Co Ltd チエノ［３，２−ｄ］ピリミジン−２，４−ジアミン誘導体
CN102066338A (zh) * 2008-04-22 2011-05-18 波托拉医药品公司 蛋白激酶抑制剂
CN103442568A (zh) * 2010-10-08 2013-12-11 Abbvie公司 呋喃并[3,2-d]嘧啶化合物
WO2014011911A2 (en) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2015039612A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
WO2015048281A1 (en) * 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Also Published As

Publication number Publication date
US10988482B2 (en) 2021-04-27
WO2017024589A1 (zh) 2017-02-16
JP6851367B2 (ja) 2021-03-31
KR20180035920A (ko) 2018-04-06
EP3336091B1 (en) 2020-12-02
US20200062775A1 (en) 2020-02-27
EP3336091A4 (en) 2019-01-23
KR102110573B1 (ko) 2020-05-13
EP3336091A1 (en) 2018-06-20
CN107531725B (zh) 2021-03-19
JP2018523672A (ja) 2018-08-23

Similar Documents

Publication Publication Date Title
CN107531725A (zh) Irak4抑制剂及其应用
CN107531710A (zh) Irak4抑制剂及其应用
CN104262328B (zh) 抑制btk和/或jak3激酶活性的化合物
US7468382B2 (en) Pyridine derivatives useful as inhibitors of PKC-theta
US20040235841A1 (en) Cyclic compounds and compositions as protein kinase inhibitors
AU2017203272A1 (en) Inhibitors of LRRK2 kinase activity
JP7319395B2 (ja) Ｓａｒｍ１の阻害剤
JP2023051962A (ja) ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用
JP2020506940A (ja) Ｏｇａ阻害化合物
CN107801397A (zh) Lrrk2抑制剂及其制备和使用方法
CN101784545A (zh) 用作raf激酶抑制剂的嘧啶衍生物
EP2190825A1 (en) 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
KR20140025559A (ko) 신규 Syk 억제제로서의 치환된 피리도피라진
JP2024119812A (ja) Ｓａｒｍ１の阻害剤
AU2018286221A1 (en) Aminopyrimidine compound, preparation method therefor and use thereof
AU2017213498A1 (en) Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
WO2019011228A1 (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN111518100A (zh) 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
US11919894B2 (en) Pro drugs of PDE10 compounds
JP2021527662A (ja) Ｏｇａ阻害化合物
WO2023001061A1 (en) Cdk7 selective inhibitors as anticancer agents
CN113227100A (zh) 噻吩并吡啶酮化合物
CN117304157A (zh) 作为tcr-nck相互作用的抑制剂的色烯衍生物
RU2827549C2 (ru) Соединения тиенопиридинона
TWI772370B (zh) 作為胞內體類鐸（toll-like）受體抑制劑之化合物及組合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant